References
- Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 2010;28:2467–2474.
- Assimakopoulos A, Polyzoidis K, Kyritsis AP. Stem cells in gliomas. J Stem Cells Res 2014;1(2):1009.
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–466.
- Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007;26:186–197.
- Songdej D, Sirachainan N, Wongwerawattanakoon P, Sasanakul W, Kadegasem P, Sungkarat W, et al. Combined chelation therapy with daily oral deferiprone and twice weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience. Acta Haematol 2014;133(2):226–236.
- Alexiou GA, Tsamis KI, Vartholomatos E, Peponi E, Tzima E, Tasiou I, et al. Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells. J Neurooncol 2015;123(2):217–224.
- Tsamis KI, Alexiou GA, Vartholomatos E, Kyritsis AP. Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. Cancer Invest 2013;31(9):630–638.
- Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2013;30(4):CD007415.
- Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35–61.
- Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001;61:1957–1963.
- Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol 2012;107:61–67.
- Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013;13(5):342–355.
- Galaris D, Skiada V, Barbouti A. Redox signaling and cancer: the role of “labile” iron. Cancer Lett 2008;266(1):21–29.
- Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002;1603(1):31–46.
- Fukuchi K, Tomoyasu S, Watanabe H, Kaetsu S, Tsuruoka N, Gomi K. Iron deprivation results in an increase in p53 expression. Biol Chem Hoppe Seyler 1995;376:627–630.
- Simonart T, Boelaert JR, Mosselmans R, Andrei G, Noel JC, De Clercq E, et al. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol 2002;85(1):95–102.
- Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 2007;40(5):755–767.
- Mémin E, Hoque M, Jain MR, Heller DS, Li H, Cracchiolo B, et al. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation. Cancer Res 2014;74(2):552–562.
- Kontoghiorghes GJ, Agarwal MB, Grady RW, Kolnagou A, Marx JJ. Deferiprone for thalassaemia. Lancet 2000;356(9227):428–429.
- Cook J. Radiation sensitization of mammalian cells by metal chelators. Radiat Res 2001;155(2):304–310.